Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System ...

J&J sells macitentan on its own as Opsumit, currently a top-selling drug for PAH with sales of $2 billion a year, and also makes $1.6 billion from prostacyclin analogue Uptravi (selexipag).

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

our expectation that ralinepag may be a best-in-class once-daily prostacyclin agonist; our expectation that our momentum will continue into 2025; our expectations concerning our ultimate liability ...